Dana Horáková

8.8k total citations
153 papers, 3.3k citations indexed

About

Dana Horáková is a scholar working on Pathology and Forensic Medicine, Rheumatology and Neurology. According to data from OpenAlex, Dana Horáková has authored 153 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Pathology and Forensic Medicine, 36 papers in Rheumatology and 31 papers in Neurology. Recurrent topics in Dana Horáková's work include Multiple Sclerosis Research Studies (111 papers), Systemic Lupus Erythematosus Research (24 papers) and Peripheral Neuropathies and Disorders (22 papers). Dana Horáková is often cited by papers focused on Multiple Sclerosis Research Studies (111 papers), Systemic Lupus Erythematosus Research (24 papers) and Peripheral Neuropathies and Disorders (22 papers). Dana Horáková collaborates with scholars based in Czechia, United States and Italy. Dana Horáková's co-authors include Eva Havrdová, Manuela Vaněčková, Jan Krásenský, Zdeněk Seidl, Robert Zivadinov, Niels Bergsland, Michael G. Dwyer, Michaela Týblová, Tomáš Uher and Tomáš Kalinčík and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Neurology.

In The Last Decade

Dana Horáková

137 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dana Horáková Czechia 33 2.4k 806 735 544 500 153 3.3k
Dejan Jakimovski United States 29 2.1k 0.9× 764 0.9× 511 0.7× 472 0.9× 324 0.6× 179 3.0k
Bonnie I. Glanz United States 31 2.2k 0.9× 732 0.9× 566 0.8× 704 1.3× 272 0.5× 110 3.3k
Darin T. Okuda United States 24 2.7k 1.1× 1.1k 1.4× 650 0.9× 484 0.9× 589 1.2× 113 3.4k
Francesca Bagnato United States 31 2.2k 0.9× 688 0.9× 550 0.7× 569 1.0× 1.1k 2.2× 131 3.6k
Jelena Drulović Serbia 37 3.2k 1.3× 1.2k 1.5× 929 1.3× 665 1.2× 431 0.9× 174 4.7k
Teresa C. Frohman United States 36 2.8k 1.2× 1.0k 1.3× 881 1.2× 508 0.9× 584 1.2× 111 4.8k
Roberto Bergamaschi Italy 39 2.8k 1.2× 1.7k 2.2× 800 1.1× 639 1.2× 422 0.8× 175 4.4k
Daniel Ontaneda United States 30 1.9k 0.8× 717 0.9× 441 0.6× 448 0.8× 289 0.6× 144 2.6k
Scott D. Newsome United States 33 2.8k 1.2× 1.2k 1.5× 973 1.3× 420 0.8× 652 1.3× 168 4.4k
Paulus Rommer Austria 34 2.4k 1.0× 1.7k 2.1× 664 0.9× 553 1.0× 174 0.3× 172 3.7k

Countries citing papers authored by Dana Horáková

Since Specialization
Citations

This map shows the geographic impact of Dana Horáková's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana Horáková with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana Horáková more than expected).

Fields of papers citing papers by Dana Horáková

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dana Horáková. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana Horáková. The network helps show where Dana Horáková may publish in the future.

Co-authorship network of co-authors of Dana Horáková

This figure shows the co-authorship network connecting the top 25 collaborators of Dana Horáková. A scholar is included among the top collaborators of Dana Horáková based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana Horáková. Dana Horáková is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lőrincz, Balázs B., Jan Krásenský, Tobias Kober, et al.. (2024). Lipid measures are associated with cognitive functioning in multiple sclerosis patients. Multiple Sclerosis and Related Disorders. 91. 105879–105879. 1 indexed citations
2.
Butzkueven, Helmut, Tomáš Kalinčík, Francesco Patti, et al.. (2024). Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies. Therapeutic Advances in Neurological Disorders. 17. 4223502419–4223502419. 2 indexed citations
3.
Signori, Alessio, Marta Ponzano, Tomáš Kalinčík, et al.. (2024). Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry. Journal of Neurology Neurosurgery & Psychiatry. 95(7). 620–625. 2 indexed citations
4.
Horáková, Dana, et al.. (2024). B‑lymphocyte‑targeted MS therapy: from theory to a decade of ocrelizumab in practice. Neurologie pro praxi. 25(2). 124–129.
5.
Pontieri, Luigi, et al.. (2023). COVID‐19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark. European Journal of Neurology. 31(3). e16163–e16163. 2 indexed citations
6.
Vaněčková, Manuela, Michaela Andělová, Jan Krásenský, et al.. (2022). Periventricular gradient of T1 tissue alterations in multiple sclerosis. NeuroImage Clinical. 34. 103009–103009. 14 indexed citations
7.
Boyко, Alexey, Dana Horáková, Jarmila Szilasiová, et al.. (2021). Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals. Multiple Sclerosis and Related Disorders. 50. 102778–102778. 9 indexed citations
8.
Hilbert, Tom, Manuela Vaněčková, Jan Krásenský, et al.. (2020). Quantitative t(1) deviations in brain lesions and nawm improve the clinico-radiological correlation in early ms. Multiple Sclerosis Journal. 26. 418–418.
9.
Horáková, Dana, Tomáš Uher, Jan Krásenský, et al.. (2020). Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study. Multiple Sclerosis and Related Disorders. 46. 102543–102543. 16 indexed citations
10.
Andělová, Michaela, Tomáš Uher, Jan Krásenský, et al.. (2019). Atlas-based tract damage mapping improves 4-year forecast of EDSS in multiple sclerosis. Multiple Sclerosis Journal. 25. 182–183. 1 indexed citations
11.
Horáková, Dana. (2018). Registr pacientů s roztroušenou sklerózou ReMuS – kam jsme se posunuli za pět let existence registru. Neurologie pro praxi. 19(6). 467–472. 1 indexed citations
12.
Burgetová, Andrea, Petr Dušek, Manuela Vaněčková, et al.. (2017). Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis. American Journal of Neuroradiology. 38(6). 1079–1086. 33 indexed citations
13.
Vaněčková, Manuela & Dana Horáková. (2016). Magnetic resonance imaging for detection of opportunistic infection of patients with multiple sclerosis. Neurologie pro praxi. 17(6). 377–383.
14.
Nytrová, Petra, Eliška Potluková, David Kemlink, et al.. (2014). Complement activation in patients with neuromyelitis optica. Journal of Neuroimmunology. 274(1-2). 185–191. 60 indexed citations
15.
Uher, Tomáš, Ralph H. B. Benedict, Dana Horáková, et al.. (2014). Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. Journal of the Neurological Sciences. 347(1-2). 229–234. 9 indexed citations
16.
Doležal, Ondřej, Dana Horáková, Zuzana Gdovinová, & Jarmila Szilasiová. (2012). Serious Complication of Percutaneous Angioplasty with Stent Implantation in so Called "Chronic Cerebrospinal Venous Insufficiency" in Multiple Sclerosis Patient. Prague Medical Report. 113(4). 289–293. 5 indexed citations
17.
Horáková, Dana. (2011). Roztroušená skleróza - naše současné možnosti při diagnostice, stanovení prognózy nemoci a sledování efektivity léčby. Neurologie pro praxi. 12(4). 265–269.
18.
Diblík, Pavel & Dana Horáková. (2010). [Optic neuritis in multiple sclerosis].. PubMed. 66(2). 51–4. 1 indexed citations
19.
Horáková, Dana, Michal Kýr, Eva Havrdová, et al.. (2010). Apolipoprotein E ε4-Positive Multiple Sclerosis Patients Develop More Gray-Matter and Whole-Brain Atrophy: a 15-Year Disease History Model Based on a 4-Year Longitudinal Study. Folia Biologica. 56(6). 242–251. 7 indexed citations
20.
Lojda, Z, et al.. (1976). Effect of beta-blocking agents in experimental atherosclerosis of cocks.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 22(3). 117–26. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dejan Jakimovski Breakdown of academic impact, for papers by Bonnie I. Glanz Breakdown of academic impact, for papers by Darin T. Okuda Breakdown of academic impact, for papers by Francesca Bagnato Breakdown of academic impact, for papers by Jelena Drulović Breakdown of academic impact, for papers by Teresa C. Frohman Breakdown of academic impact, for papers by Roberto Bergamaschi Breakdown of academic impact, for papers by Daniel Ontaneda Breakdown of academic impact, for papers by Scott D. Newsome Breakdown of academic impact, for papers by Paulus Rommer
Rankless by CCL
2026